Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. / Helleberg, Marie; Niemann, Carsten Utoft; Moestrup, Kasper Sommerlund; Kirk, Ole; Lebech, Anne Mette; Lane, Clifford; Lundgren, Jens.
In: Journal of Infectious Diseases, Vol. 222, No. 7, 2020, p. 1103-1107.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy
AU - Helleberg, Marie
AU - Niemann, Carsten Utoft
AU - Moestrup, Kasper Sommerlund
AU - Kirk, Ole
AU - Lebech, Anne Mette
AU - Lane, Clifford
AU - Lundgren, Jens
PY - 2020
Y1 - 2020
N2 - The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.
AB - The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.
KW - Case report
KW - COVID-19
KW - Immunocompromised
KW - Remdesivir
KW - SARS-CoV-2
U2 - 10.1093/infdis/jiaa446
DO - 10.1093/infdis/jiaa446
M3 - Journal article
C2 - 32702095
AN - SCOPUS:85090177512
VL - 222
SP - 1103
EP - 1107
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 7
ER -
ID: 258330405